AN2 Therapeutics
ANTX
51 hedge funds and large institutions have $418M invested in AN2 Therapeutics in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 2 closing their positions.
700% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 2
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
38% more funds holding
Funds holding: 37 → 51 (+14)
30% more capital invested
Capital invested by funds: $320M → $418M (+$97.7M)
1.49% more ownership
Funds ownership: 67.09% → 68.58% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.41M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.14M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.99M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.89M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.35M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$3.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$1.82M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.82M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $1.29K | -$49.9K | -2,982 | -98% |
|
52
UBS Group
Zurich,
Switzerland
| – | -$660K | -41,046 | Closed |
|
|
HWA
53
Heritage Wealth Advisors
Richmond,
Virginia
| – | -$17K | -1,060 | Closed |
|
ANTX Hedge Fund Activity: Q4 2023 in Review
51 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q4 2023, worth a combined $418M — up 30% from $320M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ANTX positions and 2 closed out — a net gain of 14 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $4.41M. The largest seller was Marshall Wace, cutting an estimated $6.35M.
- 51 institutional investors held AN2 Therapeutics (ANTX) as of Q4 2023, up from 37 in Q3 2023.
- Funds reported $418M of AN2 Therapeutics stock for Q4 2023, up 30% quarter-over-quarter.
- 16 funds opened new AN2 Therapeutics positions in Q4 2023 and 2 closed out, a net change of +14 holders.
- The largest AN2 Therapeutics buyer in Q4 2023 was BlackRock, an estimated $4.41M added.
- The largest AN2 Therapeutics seller in Q4 2023 was Marshall Wace, an estimated $6.35M sold.
Based on aggregated 13F filings for Q4 2023.